Cabaletta Bio, Inc.
NASDAQ:CABABiotechnology
Healthcare
$1.02 +1.23%
+$0.04 today
- Market cap
- $220.03M
- Beta
- 3.23
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$1.57
52W Low $1.26High $4.23
Volume 5.46M
Average 3.33M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$131.08M
FY 2025 · Annual
Investing Cash Flow
-$50.27M
FY 2025 · Annual
Financing Cash Flow
$100.35M
FY 2025 · Annual
+759.4% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (46.29M) | (52.98M) | (67.68M) | (115.86M) | (167.86M) |
| Depreciation & Amortization | 733K | 1.18M | 1.43M | 1.71M | 1.65M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 5.8M | 6.9M | 11.34M | 19.47M | 20.94M |
| Change in Working Capital | 5.58M | (4.3M) | 101K | 1.61M | (379K) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 975K | (28K) | 1.68M | 1.01M | 1.55M |
| Other Working Capital | 4.61M | (4.27M) | (1.57M) | 600K | (1.93M) |
| Other Non-Cash Items | 62K | 2.82M | 1.26M | 4.86M | 14.57M |
| Operating Cash Flow | (34.11M) | (46.38M) | (53.55M) | (88.22M) | (131.08M) |
| Capital Expenditures | (1.17M) | (2.45M) | (687K) | (2.21M) | (1.23M) |
| Acquisitions (Net) | 0 | 24.76K | 0 | 0 | 0 |
| Purchases of Investments | 0 | (49.76M) | (84.26M) | 0 | (99.04M) |
| Sales of Investments | 7.17M | 25M | 62.5M | 49.5M | 50M |
| Other Investing Activities | 0 | (24.76K) | 0 | 0 | 0 |
| Investing Cash Flow | 6M | (27.22M) | (22.45M) | 47.29M | (50.27M) |
| Debt Repayment | 0 | 0 | 0 | (897K) | (6.26M) |
| Common Stock Issued | 48.25M | 32.86M | 185.2M | 10.88M | 106.61M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 650K | 127K | 2.43M | 1.7M | 0 |
| Financing Cash Flow | 48.9M | 32.98M | 187.63M | 11.68M | 100.35M |
| Effect of Forex Changes | 0 | 0 | 0 | (20K) | 19K |
| Net Change in Cash | 20.79M | (40.62M) | 111.63M | (29.28M) | (80.98M) |
| Free Cash Flow | (35.28M) | (48.83M) | (54.24M) | (90.43M) | (132.31M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$167.9M
+ D&A$1.6M
+ Stock-Based Comp$20.9M
+ Deferred Tax$0
- Working Capital-$379.0K
+ Other Non-Cash$14.6M
= Operating Cash Flow-$131.1M
- Capex-$1.2M
= Free Cash Flow-$132.3M
Analysis
FY2025 free cash flow is -$132.3M. FCF conversion is 78.8% of net income. Operating cash flow was -$131.1M, with capex of -$1.2M. The largest bridge item is Stock-Based Comp at $20.9M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G/A | SC 13G/A filing | Nov 12, 2026 | |
| 8-K | Current report | Nov 9, 2026 | |
| SC 13G/A | SC 13G/A filing | Nov 6, 2026 | |
| SC 13G/A | SC 13G/A filing | Nov 6, 2026 | |
| 8-K | Current report | Nov 5, 2026 |
Does CABA generate free cash flow?
Cabaletta Bio, Inc. (CABA) generated -$132.31M of free cash flow in fiscal 2025.
How much operating cash flow does CABA produce?
Operating cash flow was -$131.08M, before capital expenditures of $1.23M.
Continue the stock analysis
Jump to another research area for this company.